• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    5/5/25 7:15:04 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $EPRX alert in real time by email
    6-K 1 f6k_050325.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

    Commission File Number: 001-41923

    EUPRAXIA PHARMACEUTICALS INC.
    (Exact name of Registrant as specified in its charter)

    N/A
    (Translation of Registrant’s name)

    201-2067 Cadboro Bay Road
    Victoria, British Columbia, Canada V8R 5G4
    Telephone: (250) 590-3968 

    (Address and telephone number of registrant’s principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [   ]      Form 40-F [ X ]

     

     


    DOCUMENTS INCLUDED AS PART OF THIS REPORT

    Exhibit  
      
    99.1 Press Release dated May 5, 2025


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      EUPRAXIA PHARMACEUTICALS INC.
       
      
    Date: May 5, 2025 By: /s/ Alex Rothwell                     
      Name: Alex Rothwell
      Title: Chief Financial Officer
      
    Get the next $EPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EPRX

    DatePrice TargetRatingAnalyst
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $EPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

      VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader (KOL) event on Friday, May 9, 2025 at 9:00 AM ET. To register, click here. The event will feature Evan Dellon, MD, MPH (University of North Carolina, Chapel Hill), who will join Company management to discuss additional clinical data from Eupraxia's Phase 1b/2a RESOLVE Study evaluating EP-104GI for the treatment of

      5/7/25 2:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

      Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

      5/6/25 6:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

      Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GIAt 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoEAlso, at 9 months patients demonstrated sustained or improved treatment outcomes compared to 3- and 6-month resultsAdditional long-term data to be released with higher doses in Q3 2025Eupraxia to host webinar with guest, Dr. Evan Dellon, to discuss data from RESOLVE trial on Fri

      5/5/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Financials

    Live finance-specific insights

    See more
    • Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

      Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

      5/6/25 6:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

      VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

      3/20/25 5:30:48 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

      VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the third quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the third quarter, we advanced our Phase 1b/2a RESOLVE trial for EP-104GI as a treatment for eosinophilic esophagitis, reporting further positiv

      11/7/24 5:00:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Eupraxia Pharmaceuticals Announces CFO Succession

      -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

      2/18/25 7:00:00 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

      VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

      10/31/24 7:36:00 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

      SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

      11/14/24 4:17:44 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

      SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

      11/7/24 4:10:15 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    SEC Filings

    See more
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/7/25 2:15:04 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/6/25 4:59:51 PM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

      6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

      5/5/25 7:15:04 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care

    $EPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Eupraxia Pharmaceuticals with a new price target

      Craig Hallum initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      2/21/25 8:14:31 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care
    • Rodman & Renshaw initiated coverage on Eupraxia Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      11/14/24 7:29:37 AM ET
      $EPRX
      Pharmaceuticals and Biotechnology
      Health Care